• By ICR Secretariat
  • Posted Monday, July 8, 2019

FDA officials see 'missed opportunity' with patient outcomes in clinical trials


SAN DIEGO — Drug regulators are beginning to look at more than primary endpoints when evaluating new products.

Particularly in the last few years, the Food and Drug Administration has shown an interest in patient-reported outcomes, meaning the information patients can provide about their disease burden, the drugs they take, and associated feelings and experiences.